The only Chinese company featured in the top-tier and prestigious event that attracts ophthalmology innovators from around the world 

HONG KONG, 15 November, 2021 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, was selected as a presenting company at the Eyecelerator@AAO 2021 on November 11, 2021 in New Orleans, United States.

Eyecelerator is one of the most trusted and prestigious ophthalmology conferences in the world. It is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS), with a mission to connect entrepreneurs, investors, companies and physicians to advance ophthalmic innovation through live conferences, virtual programming and a next-generation networking platform. This year, the prestigious conference brought together top ophthalmologists and industry leaders in the ophthalmology industry from all over the world including Alcon, Allergan and Johnson & Johnson Vision, Zhaoke Ophthalmology is also the only Chinese company featured in this event.

The conference program is composed of panel discussions spanning across multiple areas including commercial and capital markets, cornea, retina and myopia control. At the Cornea Showcases session, Dr. Li Xiaoyi (Benjamin), Chairman and CEO of Zhaoke Ophthalmology presented the Company’s innovative pipeline, highlighting CsA Ophthalmic Gel for the treatment of dry eye disease, among a concentrated ophthalmic audience, primed to accelerate market introductions. The presentation also demonstrated the Company’s track record of in-licensing global drugs and highlighted its desire to actively out-license innovative treatments. This best-in-class forum attracts the largest, most commercially-successful businesses in ophthalmology today, including companies poised and eager to expand their business portfolios to include new innovations.

Dr. Li Xiaoyi (Benjamin), Chairman and CEO of Zhaoke Ophthalmology, said, “We were honored to be selected to present at the Eyecelerator Conference. This prestigious event provided us with the perfect opportunity to increase our visibility in the ophthalmology industry and the United States market by connecting us with a concentrated ophthalmic audience and investors. We were pleased to share our innovations and insights with top experts from different parts of the world and demonstrate our strong research and development capabilities as the ophthalmology leader in China. We strive to harness scientific rigor to develop treatments that address the major eye conditions affecting both the front and back of the eye, and to transform visual health for patients all around the world.”